NCT03881683View on ClinicalTrials.gov

Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 21, 2020

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions
Ovarian Cancer
Interventions
DIAGNOSTIC_TEST

HRD and BRCA mutations

Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy

Trial Locations (1)

54506

Institut de Cancerologie de Lorraine, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Institut de Cancérologie de Lorraine

OTHER

NCT03881683 - Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter